{
    "clinical_study": {
        "@rank": "60447", 
        "acronym": "DIURESIS-CHF", 
        "arm_group": [
            {
                "arm_group_label": "Acetazolamide/low-dose loop diuretics, upfront spironolactone", 
                "arm_group_type": "Experimental", 
                "description": "2x2 factorial design: This group is the experimental group for both study interventions (acetazolamide and upfront spironolactone).\nSee interventions for more details."
            }, 
            {
                "arm_group_label": "High-dose loop diuretics, upfront spironolactone", 
                "arm_group_type": "Experimental", 
                "description": "2x2 factorial design: This group is the experimental group for the study intervention with upfront spironolactone. This group receives high-dose loop diuretics as an active comparator to the study intervention with acetazolamide.\nSee interventions for more details."
            }, 
            {
                "arm_group_label": "Acetazolamide/low-dose loop diuretics, no spironolactone", 
                "arm_group_type": "Experimental", 
                "description": "2x2 factorial design: This group is the experimental group for the study intervention with acetazolamide. This group receives no intervention with regards to the spironolactone arm.\nSee interventions for more details."
            }, 
            {
                "arm_group_label": "High-dose loop diuretics, no spironolactone", 
                "arm_group_type": "Active Comparator", 
                "description": "2x2 factorial design: This group receives high-dose loop diuretics as an active comparator to the study intervention with acetazolamide. This group receives no intervention with regards to the spironolactone arm.\nSee interventions for more details."
            }
        ], 
        "brief_summary": {
            "textblock": "This study has two primary objectives:\n\n        1. To compare combination therapy with acetazolamide and low-dose loop diuretics versus\n           high-dose loop diuretics (standard of care) in patients with acute decompensated heart\n           failure at high risk for diuretic resistance.\n\n        2. To demonstrate the safety and efficacy of upfront therapy with spironolactone in\n           addition to loop diuretic therapy in patients with acute decompensated heart failure at\n           high risk for diuretic resistance."
        }, 
        "brief_title": "Acetazolamide and Spironolactone to Increase Natriuresis in Congestive Heart Failure", 
        "completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Heart Failure", 
        "condition_browse": {
            "mesh_term": "Heart Failure"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Older than 18 years and able to give informed consent\n\n          -  Clinical diagnosis of acute decompensated heart failure within the previous 8 h\n\n          -  At least two clinical signs of congestion (edema, ascites, jugular venous distension,\n             or pulmonary vascular congestion on chest radiography)\n\n          -  Maintenance therapy with oral loop diuretics at a dose of at least 1 mg bumetanide (1\n             mg bumetanide = 40 mg furosemide = 20 mg torsemide) for at least 1 month before\n             hospital admission\n\n          -  NT-proBNP >1000 ng/L\n\n          -  Left ventricular ejection fraction <50%\n\n          -  At least one out of three of the following criteria:\n\n               -  Serum sodium <136 mmol/L\n\n               -  Serum urea/creatinine ratio >50 (comparable to a BUN/creatinine ratio >25)\n\n               -  Admission serum creatinine increased with >0.3 mg/dL compared to previous value\n                  within 3 months before admission\n\n        Exclusion Criteria:\n\n          -  History of cardiac transplantation and/or ventricular assist device\n\n          -  Concurrent diagnosis of an acute coronary syndrome defined as typical chest pain\n             and/or electrocardiographic changes in addition to a troponin rise >99th percentile\n\n          -  Mean arterial blood pressure <65 mmHg, or systolic blood pressure <90 mmHg at the\n             moment of admission\n\n          -  Use of intravenous inotropes, vasopressors or nitroprusside at any time point during\n             the study\n\n          -  A baseline estimated glomerular filtration rate <15 mL/min/1.73m\u00b2 according to the\n             Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula at the moment of\n             inclusion\n\n          -  Use of renal replacement therapy or ultrafiltration before study inclusion\n\n          -  Treatment with acetazolamide within the previous month\n\n          -  Treatment with \u22652 mg bumetanide or an equivalent dose during the index\n             hospitalization before randomization\n\n          -  Use of diuretics, vasopressin antagonists or mineralocorticoid receptor antagonist\n             not specified by the protocol\n\n          -  Exposure to nephrotoxic agents (i.e. contrast dye) anticipated within 3 days"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01973335", 
            "org_study_id": "ZOL-DIURESIS-CHF"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Acetazolamide/low-dose loop diuretics, upfront spironolactone", 
                    "Acetazolamide/low-dose loop diuretics, no spironolactone"
                ], 
                "description": "Patients receive 500 mg of intravenous acetazolamide immediately after randomization, with 250 mg intravenous acetazolamide administered on each consecutive day in the morning for as long as the patient is considered volume overloaded by his/her treating cardiologist.\nPatients receive 2 mg of intravenous bumetanide immediately after randomization, with 1 mg intravenous bumetanide administered on each consecutive day in the morning for as long as the patient is considered volume overloaded by his/her treating cardiologist.\nIf diuresis <1,5 L while the patient is still considered volume overloaded by his/her treating cardiologist, the dose of acetazolamide is maintained at 500 mg and the dose of bumetanide is maintained at 2mg.\nIn case of therapy-refractory congestion, treatment is at the discretion of the treating physician, but addition of chlorthalidone 50 mg PO is recommended by the investigators as a first-line option.", 
                "intervention_name": "Combination therapy with acetazolamide and low-dose loop diuretics", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Diamox (acetazolamide)", 
                    "Burinex/Bumex (loop diuretics)"
                ]
            }, 
            {
                "arm_group_label": [
                    "High-dose loop diuretics, upfront spironolactone", 
                    "High-dose loop diuretics, no spironolactone"
                ], 
                "description": "Patients receive the double of their daily maintenance dose of oral loop diuretics converted to mg bumetanide as an intravenous bolus after randomization.\nPatients continue to receive this dose daily on the next 3 days divided between two administrations with at least a 6 h interval for as long as they are considered volume overloaded by the treating cardiologist.\nIf diuresis <1,5 L while the patient is still considered volume overloaded by the treating cardiologist, the dose of bumetanide is doubled.\nIn case of therapy-refractory congestion, treatment is at the discretion of the treating physician, but addition of chlorthalidone 50 mg PO is recommended by the investigators as a first-line option.", 
                "intervention_name": "High-dose loop diuretics", 
                "intervention_type": "Drug", 
                "other_name": "Burinex/Bumex"
            }, 
            {
                "arm_group_label": [
                    "Acetazolamide/low-dose loop diuretics, upfront spironolactone", 
                    "High-dose loop diuretics, upfront spironolactone"
                ], 
                "description": "Patients randomized to this group receive oral spironolactone (25mg) immediately after randomization and in the morning of each subsequent day unless the serum potassium level is >5 mmol/L.\nNote: Investigators and treating physicians are blinded to treatment allocation for this arm, but no matching placebo is provided, so patients are not.", 
                "intervention_name": "Upfront therapy with oral spironolactone", 
                "intervention_type": "Drug", 
                "other_name": "Aldactone"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Acetazolamide", 
                "Bumetanide", 
                "Diuretics", 
                "Spironolactone", 
                "Sodium Potassium Chloride Symporter Inhibitors"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "acetazolamide", 
            "bumetanide", 
            "cardio-renal syndrome", 
            "diuretics", 
            "heart failure", 
            "natriuresis", 
            "spironolactone"
        ], 
        "lastchanged_date": "December 19, 2013", 
        "location": {
            "contact": {
                "email": "frederik.verbrugge@zol.be", 
                "last_name": "Frederik H. Verbrugge, M.D.", 
                "phone": "+3289321516"
            }, 
            "contact_backup": {
                "email": "petra.nijst@zol.be", 
                "last_name": "Petra Nijst, M.D.", 
                "phone": "+3289321525"
            }, 
            "facility": {
                "address": {
                    "city": "Genk", 
                    "country": "Belgium", 
                    "state": "Limburg", 
                    "zip": "3600"
                }, 
                "name": "Ziekenhuis Oost-Limburg"
            }, 
            "investigator": [
                {
                    "last_name": "Frederik H. Verbrugge, M.D.", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Wilfried Mullens, M.D. Ph.D.", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Petra Nijst, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Philippe B. Bertrand, M.D. M.Sc.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Lars Grieten, Ph.D. M.Sc.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Matthias Dupont, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Joris Penders, M.D. Ph.D.", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Belgium"
        }, 
        "number_of_arms": "4", 
        "official_title": "Diamox/Aldactone to Increase the URinary Excretion of Sodium: an Investigational Study in Congestive Heart Failure", 
        "other_outcome": [
            {
                "description": "Total natriuresis (mmol) after 48 h.", 
                "measure": "Natriuresis 48 h", 
                "safety_issue": "No", 
                "time_frame": "48h"
            }, 
            {
                "description": "Total natriuresis (mmol) after 72 h.", 
                "measure": "Natriuresis 72 h", 
                "safety_issue": "No", 
                "time_frame": "72h"
            }, 
            {
                "description": "Total amount of urine output (L) after 24 h.", 
                "measure": "Diuresis 24 h", 
                "safety_issue": "No", 
                "time_frame": "24h"
            }, 
            {
                "description": "Total amount of urine output (L) after 48 h.", 
                "measure": "Diuresis 48 h", 
                "safety_issue": "No", 
                "time_frame": "48h"
            }, 
            {
                "description": "Total amount of urine output (L) after 72 h.", 
                "measure": "Diuresis 72 h", 
                "safety_issue": "No", 
                "time_frame": "72h"
            }, 
            {
                "description": "Body weight change after 72 h compared to admission.", 
                "measure": "Weight change after 72 h", 
                "safety_issue": "No", 
                "time_frame": "72h"
            }, 
            {
                "measure": "Visual analogue scale score for dyspnea after 24 h", 
                "safety_issue": "No", 
                "time_frame": "24h"
            }, 
            {
                "measure": "Visual analogue scale score for dyspnea after 48 h", 
                "safety_issue": "No", 
                "time_frame": "48h"
            }, 
            {
                "measure": "Visual analogue scale score for dyspnea after 72 h", 
                "safety_issue": "No", 
                "time_frame": "72h"
            }, 
            {
                "measure": "4-point Likert scale for edema after 24 h", 
                "safety_issue": "No", 
                "time_frame": "24h"
            }, 
            {
                "measure": "4-point Likert scale for edema after 48 h", 
                "safety_issue": "No", 
                "time_frame": "48h"
            }, 
            {
                "measure": "4-point Likert scale for edema after 72 h", 
                "safety_issue": "No", 
                "time_frame": "72h"
            }, 
            {
                "description": "Need for combinational diuretic therapy with thiazide-type diuretics, bail-out ultrafiltration or renal replacement therapy", 
                "measure": "Incidence of therapy-refractory congestion", 
                "safety_issue": "Yes", 
                "time_frame": "72h"
            }, 
            {
                "measure": "All-cause mortality", 
                "safety_issue": "No", 
                "time_frame": "After 1 year of follow-up"
            }
        ], 
        "overall_contact": {
            "email": "frederik.verbrugge@zol.be", 
            "last_name": "Frederik H. Verbrugge, M.D.", 
            "phone": "+3289321516"
        }, 
        "overall_contact_backup": {
            "email": "petra.nijst@zol.be", 
            "last_name": "Petra Nijst, M.D.", 
            "phone": "+3289321525"
        }, 
        "overall_official": [
            {
                "affiliation": "Ziekenhuis Oost-Limburg", 
                "last_name": "Wilfried Mullens, M.D. Ph.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Ziekenhuis Oost-Limburg", 
                "last_name": "Frederik H. Verbrugge, M.D.", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Belgium: Federal Agency for Medicines and Health Products, FAMHP", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Total natriuresis (mmol) after 24 h: After initiation of therapy, urine is collected for 3 consecutive 24 h intervals. For each interval, natriuresis is calculated as the total amount of diuresis (L) multiplied by the urinary sodium concentration (mmol/L).", 
                "measure": "Acetazolamide arm: natriuresis 24 h", 
                "safety_issue": "No", 
                "time_frame": "24h"
            }, 
            {
                "description": "At three consecutive mornings after study inclusion, blood samples will be taken to assess serum potassium levels.", 
                "measure": "Spironolactone arm: incidence of hypo- (serum potassium <3.5 mmol/L) or hyperkalemia (serum potassium >5.0 mmol/L)", 
                "safety_issue": "Yes", 
                "time_frame": "72h"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01973335"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Ziekenhuis Oost-Limburg", 
            "investigator_full_name": "Wilfried Mullens, MD PhD", 
            "investigator_title": "Prof. Dr.", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Relative NT-proBNP change (%) after 72 h compared to baseline.", 
                "measure": "NT-proBNP change after 72 h", 
                "safety_issue": "No", 
                "time_frame": "72h"
            }, 
            {
                "description": "Worsening renal function is defined as a rise in serum creatine >0.3 mg/dL or a >20% decrease in estimated glomerular filtration rate by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula compared to baseline at any time point before 72 h. Serum creatinine values are assessed at three consecutive mornings after study inclusion.", 
                "measure": "Worsening renal function", 
                "safety_issue": "Yes", 
                "time_frame": "72h"
            }, 
            {
                "description": "Persistent renal impairment is defined as a persistently elevated serum creatine >0.3mg/dL or >20% decrease in estimated glomerular filtration rate by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula, above the baseline value of the patient and will be assessed on a scheduled follow-up appointment 4 weeks after hospital discharge.", 
                "measure": "Persistent renal impairment", 
                "safety_issue": "Yes", 
                "time_frame": "4 weeks after hospital discharge"
            }, 
            {
                "description": "At three consecutive mornings after study inclusion, blood samples will be taken to assess plasma aldosterone levels. The highest value will constitute the peak plasma aldosterone concentration (ng/L).", 
                "measure": "Peak plasma aldosterone concentration after 72 h", 
                "safety_issue": "No", 
                "time_frame": "72h"
            }, 
            {
                "description": "At three consecutive mornings after study inclusion, blood samples will be taken to assess plasma renin activity. The highest value will constitute the peak plasma renin activity (ng/mL/h).", 
                "measure": "Peak plasma renin activity after 72 h", 
                "safety_issue": "No", 
                "time_frame": "72h"
            }
        ], 
        "source": "Hasselt University", 
        "sponsors": {
            "collaborator": {
                "agency": "Ziekenhuis Oost-Limburg", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Hasselt University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}